Vertex Pharmaceuticals Financial Statements Trends

VRTX -- USA Stock  

Earning Report: October 23, 2019  

This module enables investors to look at Vertex Pharmaceuticals various fundamental indicators over time in order to gain insight into the company future performance. Macroaxis historical fundamental analysis tools allow evaluation of not only typical financial statement drivers such as Direct Expenses of 291.1 M, Cost of Revenue of 125.5 M or Gross Profit of 1.2 B, but also many exotic indicators such as Interest Coverage of 11.8293, Long Term Debt to Equity of 0.354 or PPandE Turnover of 4.1348. This module is a perfect complement to use when analyzing Vertex Pharmaceuticals Valuation or Volatility. It can also complement various Vertex Pharmaceuticals Technical models. Also please take a look at analysis of Vertex Pharmaceuticals Correlation with competitors.
Revenues

Vertex Pharmaceuticals Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets2.5 B6.2 B2.7 B
Increasing
Slightly volatile
Cash and EquivalentsB2.7 B1.1 B
Increasing
Slightly volatile
Investments356.8 M243.8 M557.5 M
Decreasing
Slightly volatile
Investments Current340 M225.6 M546.5 M
Decreasing
Slightly volatile
Investments Non Current30 M23.3 M27.5 M
Decreasing
Slightly volatile
Deferred Revenue72.5 M14.5 M96 M
Decreasing
Slightly volatile
Deposit Liabilities65.7 M66.1 M72.2 M
Decreasing
Slightly volatile
Property Plant and Equipment Net438.2 M628.5 M446.3 M
Increasing
Slightly volatile
Inventory78.1 M89.2 M75.4 M
Decreasing
Stable
Trade and Non Trade Receivables123.6 M181 M117.6 M
Increasing
Slightly volatile
Trade and Non Trade Payables46.5 M55.3 M56.7 M
Increasing
Slightly volatile
Goodwill and Intangible Assets437.6 M384.9 M412.5 M
Decreasing
Slightly volatile
Total Liabilities1.5 B1.8 B1.4 B
Increasing
Slightly volatile
Shareholders Equity2.9 B4.4 B1.5 B
Increasing
Slightly volatile
Accumulated Retained Earnings Deficit(4.7 B)(6.2 B)(4.1 B)
Decreasing
Slightly volatile
Accumulated Other Comprehensive Income11.1 M19.1 M6.9 M
Increasing
Slightly volatile
Current Assets1.4 B3.8 B1.7 B
Increasing
Slightly volatile
Assets Non Current719.1 M958.7 M827.2 M
Increasing
Slightly volatile
Current Liabilities506.3 M1.1 B530.7 M
Increasing
Slightly volatile
Liabilities Non Current596.3 M689.5 M730.8 M
Increasing
Stable
Tax Liabilities10.8 M10.9 M11.9 M
Decreasing
Slightly volatile
Total Debt657 M756.7 M618.7 M
Increasing
Slightly volatile
Debt Current178.7 M287.5 M120.2 M
Increasing
Slightly volatile
Debt Non Current415.6 M469.2 M494.5 M
Increasing
Slightly volatile
Shareholders Equity USD921.9 M1.2 BB
Increasing
Slightly volatile
Cash and Equivalents USD765.2 M1.1 B706.5 M
Increasing
Slightly volatile
Total Debt USD576.9 M756.7 M612 M
Increasing
Slightly volatile
Accounts Payable87.5 M111 M67.9 M
Increasing
Slightly volatile
Receivables286.3 M414.9 M159.1 M
Increasing
Slightly volatile
Inventories94.9 M124.4 M82.6 M
Decreasing
Very volatile

Vertex Pharmaceuticals Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Revenues3.5 BB1.4 B
Increasing
Slightly volatile
Cost of Revenue125.5 M189.4 M120.2 M
Increasing
Slightly volatile
Selling General and Administrative Expense285.3 M389.5 M313.5 M
Increasing
Slightly volatile
Research and Development Expense728.9 M942.9 M775.3 M
Increasing
Slightly volatile
Operating ExpensesB1.3 B1.1 B
Increasing
Slightly volatile
Interest Expense50.7 M73.3 M47.6 M
Increasing
Slightly volatile
Income Tax Expense4.4 M15 M3.7 M
Decreasing
Very volatile
Net Loss Income from Discontinued Operations(62.3 M)(62.7 M)(68.5 M)
Increasing
Slightly volatile
Consolidated Income(242.9 M)(96.6 M)(333.3 M)
Increasing
Stable
Net Income to Non Controlling Interests428.5 K25.2 M(7.9 M)
Increasing
Very volatile
Net Income2.2 B2.1 B50.2 M
Increasing
Slightly volatile
Net Income Common Stock(253.3 M)(128.9 M)(323.9 M)
Increasing
Stable
Weighted Average Shares257 M254.3 M222.5 M
Increasing
Slightly volatile
Weighted Average Shares Diluted231.3 M259.2 M221.5 M
Increasing
Slightly volatile
Earning Before Interest and Taxes EBIT(179 M)(16 M)(273.8 M)
Increasing
Stable
Revenues USDB1.5 BB
Increasing
Slightly volatile
Net Income Common Stock USD(253.3 M)(128.9 M)(323.9 M)
Increasing
Stable
Earning Before Interest and Taxes USD(179 M)(16 M)(273.8 M)
Increasing
Stable
Gross Profit1.2 B1.3 B911 M
Increasing
Slightly volatile
Operating Income229.5 M635.1 M(239.4 M)
Increasing
Slightly volatile
Direct Expenses291.1 M409.5 M159.8 M
Increasing
Slightly volatile

Vertex Pharmaceuticals Cash Flow Statement

Trends Matrix
Current ValueLast YearHistorical Average 10 Year Trend
Capital Expenditure(56.1 M)(65 M)(49.9 M)
Decreasing
Slightly volatile
Net Cash Flow Business Acquisitions and Disposals(27.3 M)(11.8 M)(39.2 M)
Increasing
Slightly volatile
Net Cash Flow Investment Acquisitions and Disposals91.3 M156.7 M51.8 M
Increasing
Slightly volatile
Net Cash Flow from Financing105.5 M(71.2 M)297.8 M
Decreasing
Slightly volatile
Issuance Repayment of Debt Securities 20 M(9 M)49.4 M
Decreasing
Stable
Issuance Purchase of Equity Shares111.4 M61.4 M187.8 M
Decreasing
Slightly volatile
Net Cash Flow from Investing(146.9 M)(202.2 M)(134.8 M)
Increasing
Stable
Net Cash Flow from Operations1.1 B1.3 B120.2 M
Increasing
Slightly volatile
Effect of Exchange Rate Changes on Cash (3.2 M)(5.4 M)(2 M)
Decreasing
Slightly volatile
Net Cash Flow or Change in Cash and Cash Equivalents244.3 M422.3 M147.8 M
Increasing
Slightly volatile
Share Based Compensation149.6 M213.9 M151.7 M
Increasing
Slightly volatile
Depreciation Amortization and Accretion44.3 M55.3 M45.7 M
Increasing
Slightly volatile

Fundamental Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Earnings per Basic Share4.06618.24(0.5062)
Increasing
Slightly volatile
Earnings per Diluted Share8.528.09(0.1492)
Increasing
Slightly volatile
Earnings per Basic Share USD(1.09)(0.414)(1.5487)
Increasing
Slightly volatile
Return on Average Equity0.562564.8814(31.3792)
Increasing
Slightly volatile
Return on Average Assets0.099942.8291(13.0527)
Increasing
Slightly volatile
Return on Invested Capital(0.1769)(0.0081)(0.263)
Increasing
Slightly volatile
Gross Margin97.511586.561991.824
Decreasing
Slightly volatile
Profit Margin0.641368.8049(5.8061)
Increasing
Stable
EBITDA Margin7.894723.1907(6.4216)
Decreasing
Very volatile
Return on Sales(0.6733)(0.0072)(1.2133)
Increasing
Slightly volatile
Asset Turnover0.52370.62250.4375
Increasing
Slightly volatile
Enterprise Value over EBITDA18134777.5716
Increasing
Slightly volatile
Enterprise Value over EBIT(851)(1.5 K)(434)
Decreasing
Slightly volatile
Price to Earnings Ratio20.67(184)(42.3914)
Decreasing
Slightly volatile
Sales per Share8.681411.98465.4749
Increasing
Slightly volatile
Price to Sales Ratio13.19.5324.0926
Decreasing
Slightly volatile
Price to Book Value8.9112.2912.9829
Increasing
Slightly volatile
Debt to Equity Ratio12.90.13331.5585
Increasing
Slightly volatile
Current Ratio3.743.43053.517
Decreasing
Stable
Free Cash Flow per Share15.374.61971.0041
Increasing
Slightly volatile
Book Value per Share4.24744.914.9876
Decreasing
Stable
Tangible Assets Book Value per Share8.43689.419.1481
Increasing
Stable
Total Assets Per Share17.993324.477212.4273
Increasing
Slightly volatile
Cash Flow Per Share2.70844.97820.2223
Increasing
Slightly volatile
Return on Investment(0.1312)16.5801(23.302)
Increasing
Slightly volatile
Operating Margin29.020.841(6.4325)
Increasing
Very volatile
Calculated Tax Rate(212)(285)(155)
Decreasing
Slightly volatile
Receivables Turnover9.97678.40589.3359
Increasing
Very volatile
Inventory Turnover3.57263.46793.1642
Decreasing
Very volatile
PPandE Turnover4.13483.80613.5414
Decreasing
Very volatile
Cash and Equivalents Turnover1.47991.41241.6013
Increasing
Stable
Accounts Payable Turnover25.068632.950417.5738
Increasing
Slightly volatile
Accrued Expenses Turnover4.06224.33813.9338
Increasing
Slightly volatile
Interest Coverage11.829318.61573.8068
Increasing
Slightly volatile
Long Term Debt to Equity0.3540.13110.449
Decreasing
Very volatile
Quick Ratio3.51493.19843.3031
Decreasing
Slightly volatile
Net Current Assets as percentage of Total Assets48.407243.593745.0399
Decreasing
Very volatile
Revenue to Assets0.43750.48790.3983
Increasing
Slightly volatile

Vertex Pharmaceuticals Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Earnings before Tax(245 M)(109.7 M)(324.3 M)
Increasing
Stable
Earnings Before Interest Taxes and Depreciation Amortization EBITDA1000 M706.8 M(147.5 M)
Increasing
Slightly volatile
Earnings Before Interest Taxes and Depreciation Amortization USD(121 M)54.6 M(225.7 M)
Increasing
Slightly volatile
Market Capitalization45.3 B16.4 B17.3 B
Increasing
Slightly volatile
Enterprise Value42 B16.5 B17 B
Increasing
Slightly volatile
Invested Capital1.2 B1.5 B1.4 B
Increasing
Slightly volatile
Average Equity846.3 M1.1 B968.3 M
Increasing
Slightly volatile
Average Assets1.9 B2.4 B2.1 B
Increasing
Slightly volatile
Invested Capital Average1.2 B1.4 B1.3 B
Increasing
Slightly volatile
Tangible Asset Value1.8 B2.3 B1.9 B
Increasing
Slightly volatile
Free Cash Flow(3.1 M)206.5 M(121.7 M)
Increasing
Slightly volatile
Working Capital900.8 M935.1 M964.1 M
Increasing
Stable
Revenue Per Employee901.1 K1.2 M594.7 K
Increasing
Slightly volatile
Net Income Per Employee400.9 K838.8 K(84.2 K)
Increasing
Slightly volatile

Vertex Pharmaceuticals Fundamental Market Drivers

Short Percent Of Float1.93%
Forward Price Earnings28.45
Shares Short Prior Month3.71M
Average Daily Volume Last 10 Day791.11k
Average Daily Volume In Three Month1.16M
Date Short InterestSeptember 30, 2019
Fifty Day Average173.90
Two Hundred Day Average175.47

Vertex Pharmaceuticals Upcoming Events

Upcoming Quarterly Earning ReportOctober 23, 2019
Next Earnings ReportFebruary 4, 2020
Next Fiscal Quarter EndSeptember 30, 2019
Next Fiscal Year EndFebruary 4, 2020
Last Quarter Report DateJune 30, 2019
Last Earning Anouncement DateSeptember 30, 2018
Search macroaxis.com